| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10013291 | HBV | ENSG00000112038.18 | protein_coding | OPRM1 | No | No | 4988 | B8K2Q5 G8XRH4 G8XRH5 L0E130 P35372 |
| TVIS10012007 | HBV | ENSG00000112038.18 | protein_coding | OPRM1 | No | No | 4988 | B8K2Q5 G8XRH4 G8XRH5 L0E130 P35372 |
| TVIS30003943 | HIV | ENSG00000112038.18 | protein_coding | OPRM1 | No | No | 4988 | B8K2Q5 G8XRH4 G8XRH5 L0E130 P35372 |
| TVIS30009207 | HIV | ENSG00000112038.18 | protein_coding | OPRM1 | No | No | 4988 | B8K2Q5 G8XRH4 G8XRH5 L0E130 P35372 |
| TVIS30086264 | HIV | ENSG00000112038.18 | protein_coding | OPRM1 | No | No | 4988 | B8K2Q5 G8XRH4 G8XRH5 L0E130 P35372 |
| TVIS30076416 | HIV | ENSG00000112038.18 | protein_coding | OPRM1 | No | No | 4988 | B8K2Q5 G8XRH4 G8XRH5 L0E130 P35372 |
| TVIS30083332 | HIV | ENSG00000112038.18 | protein_coding | OPRM1 | No | No | 4988 | B8K2Q5 G8XRH4 G8XRH5 L0E130 P35372 |
| TVIS44001718 | HTLV-1 | ENSG00000112038.18 | protein_coding | OPRM1 | No | No | 4988 | B8K2Q5 G8XRH4 G8XRH5 L0E130 P35372 |
| TVIS44039289 | HTLV-1 | ENSG00000112038.18 | protein_coding | OPRM1 | No | No | 4988 | B8K2Q5 G8XRH4 G8XRH5 L0E130 P35372 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | OPRM1 |
|---|---|
| DrugBank ID | DB01183 |
| Drug Name | Naloxone |
| Target ID | BE0000770 |
| UniProt ID | P35372 |
| Regulation Type | antagonist |
| PubMed IDs | 12566163; 12799988; 12842269; 12887410; 12909198; 11752352; 18354714; 17918759; 17367258; 17161885; 17097763 |
| Citations | Narita M, Suzuki M, Mizoguchi H, Narita M, Yajima Y, Sakurada S, Tseng LF, Suzuki T: Up-regulation of mu-opioid receptor-mediated G-protein activation in protein kinase Cgamma knockout mice following repeated naloxone treatment. Neurosci Lett. 2003 Feb 27;338(2):103-6.@@Freye E, Latasch L, Von Bredow G, Neruda B: [The opioid tramadol demonstrates excitatory properties of non-opioid character--a preclinical study using alfentanil as a comparison]. Schmerz. 1998 Feb 28;12(1):19-24.@@Neal CR Jr, Owens CE, Taylor LP, Hoversten MT, Akil H, Watson SJ Jr: Binding and GTPgammaS autoradiographic analysis of preproorphanin precursor peptide products at the ORL1 and opioid receptors. J Chem Neuroanat. 2003 Jul;25(4):233-47.@@Spetea M, Toth F, Schutz J, Otvos F, Toth G, Benyhe S, Borsodi A, Schmidhammer H: Binding characteristics of [3H]14-methoxymetopon, a high affinity mu-opioid receptor agonist. Eur J Neurosci. 2003 Jul;18(2):290-5.@@Marek GJ: Behavioral evidence for mu-opioid and 5-HT2A receptor interactions. Eur J Pharmacol. 2003 Aug 1;474(1):77-83.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Helm S, Trescot AM, Colson J, Sehgal N, Silverman S: Opioid antagonists, partial agonists, and agonists/antagonists: the role of office-based detoxification. Pain Physician. 2008 Mar-Apr;11(2):225-35.@@Goodman AJ, Le Bourdonnec B, Dolle RE: Mu opioid receptor antagonists: recent developments. ChemMedChem. 2007 Nov;2(11):1552-70.@@van Dorp E, Yassen A, Dahan A: Naloxone treatment in opioid addiction: the risks and benefits. Expert Opin Drug Saf. 2007 Mar;6(2):125-32.@@Nazzaro C, Rizzi A, Salvadori S, Guerrini R, Regoli D, Zeilhofer HU, Calo G: UFP-101 antagonizes the spinal antinociceptive effects of nociceptin/orphanin FQ: behavioral and electrophysiological studies in mice. Peptides. 2007 Mar;28(3):663-9. doi: 10.1016/j.peptides.2006.11.004. Epub 2006 Dec 11.@@Economidou D, Fedeli A, Fardon RM, Weiss F, Massi M, Ciccocioppo R: Effect of novel nociceptin/orphanin FQ-NOP receptor ligands on ethanol drinking in alcohol-preferring msP rats. Peptides. 2006 Dec;27(12):3299-306. doi: 10.1016/j.peptides.2006.09.007. |
| Groups | Approved; Vet_approved |
| Direct Classification | Phenanthrenes and derivatives |
| SMILES | OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O |
| Pathways | Naloxone Action Pathway |
| PharmGKB | PA450586 |
| ChEMBL | CHEMBL80 |
